London showed once again where things are heading. On 9 November, The Talman Group hosted Talman House London, and I came home with plenty of notes and even more conversations in my head. We talked about the US, Germany and the UK, with people who move these markets every single day. And shortly afterwards came the news that Boots is now offering medical cannabis in the UK. The timing could hardly have been better.
Why we need Talman House
We are very happy to keep supporting Talman House with Cannabis-Startups. Our industry needs someone who creates the room for investors and startups, so that real deals come out of it, not just exchanged business cards. Alex and his team proved that once again in London.
London is also special for us. We met entrepreneurs again whom we had discovered long before the event. And we were able to spend more time with the investors we supported around the acquisition of an EU-GMP facility from a long-established German Mittelstand company. That filled us with pride.
What we learned about the US and Germany
The US market was very present in London, and we learned a lot about it. For me, the key lesson is this: what happens there reaches us a few years later, in products, in prices and in consolidation. Anyone founding or investing in Europe should see the US not as a distant spectacle, but as a preview.
The German market also had plenty to show. Nobody in Europe has seen so many patients, so much telemedicine and so much price pressure in such a short time. That is exactly why London watches us so closely, for better and for worse.
UK: When data becomes infrastructure
The panel on the UK market was one of the highlights for me. Jon Robson, founder and CEO of Mamedica, really went into detail.
I found his description of data exchange with the NHS fascinating. Medical cannabis in the UK runs almost entirely through private clinics, and yet data can still be shared with the NHS. That makes it possible to build a real record for every patient, so cannabis shows up in the digital patient file instead of disappearing into a parallel world.
This is where I see the biggest difference to Germany. We have a lot of telemedicine and a lot of prescriptions, but hardly any clean longitudinal data. If we want cannabis to be taken seriously as medicine, we need exactly this data: for doctors, for insurers and ultimately for policymakers.
Future Products: the UK becomes the pioneer market
One statement from Max Narr of Sanity Group at Talman really stuck with me: we will see new products and new dosage forms much earlier and much more often in the UK than in Germany or other European countries. When it comes to Future Products, the UK will be the pioneer market.
That fits the picture. In early 2026, Sanity entered a partnership with Curaleaf Laboratories to develop and manufacture new formulations specifically for UK patients and doctors. Anyone working on extracts, cartridges or entirely new formats should take a very close look at the UK.
And then came Boots. Britain's largest pharmacy chain now offers medical cannabis itself through its Online Doctor with SureLeaf. I've already written about this in detail, and for me it marks the moment cannabis in the UK moves from the niche into patients' everyday lives. Lately the biggest problem there wasn't the law anymore, but the lack of visibility.
In my view, though, it isn't quite that simple. On the one hand, Boots brings acceptance, less stigma and more investor confidence. On the other hand, patients still pay for consultations and medicines themselves, and the two-tier system between private care and the NHS becomes more entrenched rather than smaller. That is exactly why data exchange with the NHS matters so much: only with clean data from private care can we one day make the case for cannabis on NHS prescription.
Capital for the early stage: Capital Connect
Perhaps the most important news came right after London. On 17 November, The Talman Group launched its new service Capital Connect, and its first investor is True Terpenes with up to €2.5 million. The principle is simple: investors set how much they want to invest and what they are looking for. Talman then issues a call for pitch decks, pre-screens the applicants, and selected companies pitch at Talman House. We've seen first-hand that it works: last year Budtenders, from our family, pitched at the Savoy, and a six-figure investment followed.
We are proud to support this with Cannabis-Startups and absolutely thrilled about it. Early-stage capital is exactly what's missing. Last year we supported more than 35 entrepreneurs with public funding, both before and after founding. This year the funding pots have become much smaller.
Business angels alone cannot close this gap. We need the big companies to invest strategically and tactically and bring startups into their markets. True Terpenes leading the way here is a strong signal, and I hope others will follow.
My takeaway
London showed where the action is. The US shows what's coming. Germany shows what's possible in a short time. And the UK shows how to bring data, retail and new products together. If you're a founder looking for capital, take a look at Capital Connect now. See you at Talman House in Zurich and Berlin in 2027, and of course at ICBC Berlin.
Interested in what happened at Talman House London? The full video documentary with all the talks and impressions will be available on Cannabis-Startups.com soon.


